Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)

Pfizer

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: Infliximab [infliximab biosimilar 3]

Study type: Observational

Funder types: Industry

Identifiers

NCT03885037

NCT03885037 (Registry Identifier)

B5371006

Details and patient eligibility

About

To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against rheumatoid arthritis under actual status of use.

Enrollment: 77 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients with rheumatoid arthritis who started treatment with this drug
• Patients who received this drug for the first time after the day of launch of this drug.

Trial design

77 participants in 1 patient group

Infliximab [infliximab biosimilar 3]

Description:

Patients with Rheumatoid Arthritis treated by Infliximab BS

Treatment:

Drug: Infliximab [infliximab biosimilar 3]